These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

454 related articles for article (PubMed ID: 20854169)

  • 21. The role of baseline HIV-1 RNA, drug resistance, and regimen type as determinants of response to first-line antiretroviral therapy.
    Di Biagio A; Rusconi S; Marzocchetti A; Signori A; Schiavetti I; Bruzzone B; Monno L; Punzi G; Colao MG; Penco G; Zazzi M; De Luca A;
    J Med Virol; 2014 Oct; 86(10):1648-55. PubMed ID: 25042976
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term suppression of plasma viremia with highly active antiretroviral therapy despite virus evolution and very limited selection of drug-resistant genotypes.
    Pariente N; Pernas M; de la Rosa R; Gómez-Mariano G; Fernández G; Rubio A; López M; Benito JM; López-Galíndez C; Leal M; Domingo E; Martinez MA; Mas A
    J Med Virol; 2004 Jul; 73(3):350-61. PubMed ID: 15170628
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evolution of HIV-1 genotype in plasma RNA and peripheral blood mononuclear cells proviral DNA after interruption and resumption of antiretroviral therapy.
    Imaz A; Olmo M; Peñaranda M; Gutiérrez F; Romeu J; Larrousse M; Domingo P; Oteo JA; Niubó J; Curto J; Vilallonga C; Masiá M; López-Aldeguer J; Iribarren JA; Podzamczer D;
    Antivir Ther; 2012; 17(3):577-83. PubMed ID: 22301439
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Low prevalence of drug resistance transmitted virus in HIV Type 1-infected ARV-naive patients in Cambodia.
    Nouhin J; Ngin S; Martin PR; Marcy O; Kruy L; Ariey F; Peeters M; Chaix ML; Ayouba A; Nerrienet E
    AIDS Res Hum Retroviruses; 2009 May; 25(5):543-5. PubMed ID: 19388823
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development of HIV with drug resistance after CD4 cell count-guided structured treatment interruptions in patients treated with highly active antiretroviral therapy after dual-nucleoside analogue treatment.
    Nuesch R; Ananworanich J; Sirivichayakul S; Ubolyam S; Siangphoe U; Hill A; Cooper D; Lange J; Phanuphak P; Ruxrungtham K
    Clin Infect Dis; 2005 Mar; 40(5):728-34. PubMed ID: 15714420
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HIV-1 drug resistance at virological failure versus immunological failure among patients failing first-line antiretroviral therapy in a resource-limited setting.
    Sungkanuparph S; Win MM; Kiertiburanakul S; Phonrat B; Maek-a-nantawat W
    Int J STD AIDS; 2012 May; 23(5):316-8. PubMed ID: 22648883
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Utility of repeat genotypic resistance testing and clinical response in patients with three class resistance and virologic treatment failure.
    Badri SM; Adeyemi OM; Max BE; Hota BN; Barker DE
    AIDS Patient Care STDS; 2007 Aug; 21(8):544-50. PubMed ID: 17711379
    [TBL] [Abstract][Full Text] [Related]  

  • 28. No benefit of a structured treatment interruption based on genotypic resistance in heavily pretreated HIV-infected patients.
    Ghosn J; Wirden M; Ktorza N; Peytavin G; Aït-Mohand H; Schneider L; Dominguez S; Bricaire F; Calvez V; Costagliola D; Katlama C
    AIDS; 2005 Oct; 19(15):1643-7. PubMed ID: 16184034
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HIV-1 drug resistance profiles in children and adults with viral load of <50 copies/ml receiving combination therapy.
    Hermankova M; Ray SC; Ruff C; Powell-Davis M; Ingersoll R; D'Aquila RT; Quinn TC; Siliciano JD; Siliciano RF; Persaud D
    JAMA; 2001 Jul; 286(2):196-207. PubMed ID: 11448283
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HIV-1 drug resistance and associated factors among adults failing first-line highly active antiretroviral therapy in Ho Chi Minh City, Vietnam.
    Pham QD; Huynh TK; Luong TT; Tran T; Vu TX; Truong LX
    HIV Clin Trials; 2013; 14(1):34-44. PubMed ID: 23372113
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ultradeep sequencing of B and non-B HIV-1 subtypes: Viral diversity and drug resistance mutations before and after one month of antiretroviral therapy in naive patients.
    Epaulard O; Signori-Schmuck A; Larrat S; Kulkarni O; Blum MG; Fusillier K; Blanc M; Leclercq P; François O; Morand P
    J Clin Virol; 2017 Oct; 95():13-19. PubMed ID: 28830014
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High frequency of drug resistance mutations in human immunodeficiency virus type 1-infected Korean patients treated with HAART.
    Sung H; Jung YS; Kang MW; Bae IG; Chang HH; Woo JH; Cho YK
    AIDS Res Hum Retroviruses; 2007 Oct; 23(10):1223-9. PubMed ID: 17961108
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antiviral efficacy and genotypic resistance patterns of combination therapy with stavudine/tenofovir in highly active antiretroviral therapy experienced patients.
    Antinori A; Trotta MP; Nasta P; Bini T; Bonora S; Castagna A; Zaccarelli M; Quirino T; Landonio S; Merli S; Tozzi V; Di Perri G; Andreoni M; Perno CF; Carosi G
    Antivir Ther; 2006; 11(2):233-43. PubMed ID: 16640104
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Determinants of virological failure after successful viral load suppression in first-line highly active antiretroviral therapy.
    Geretti AM; Smith C; Haberl A; Garcia-Diaz A; Nebbia G; Johnson M; Phillips A; Staszewski S
    Antivir Ther; 2008; 13(7):927-36. PubMed ID: 19043927
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predictors of virologic failure and genotypic resistance mutation patterns in thai children receiving non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy.
    Jittamala P; Puthanakit T; Chaiinseeard S; Sirisanthana V
    Pediatr Infect Dis J; 2009 Sep; 28(9):826-30. PubMed ID: 19654564
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Resistance-associated mutations in HIV-1 among patients failing first-line antiretroviral therapy.
    Saini S; Bhalla P; Gautam H; Baveja UK; Pasha ST; Dewan R
    J Int Assoc Physicians AIDS Care (Chic); 2012; 11(3):203-9. PubMed ID: 21990611
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Persistence of genotypic resistance to nelfinavir among women exposed to prophylactic antiretroviral therapy during pregnancy.
    Kakehasi FM; Tupinambás U; Cleto S; Aleixo A; Lin E; Melo VH; Aguiar RA; Pinto JA
    AIDS Res Hum Retroviruses; 2007 Dec; 23(12):1515-20. PubMed ID: 18160009
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antiretroviral Resistance After First-Line Antiretroviral Therapy Failure in Diverse HIV-1 Subtypes in the SECOND-LINE Study.
    Lam EP; Moore CL; Gotuzzo E; Nwizu C; Kamarulzaman A; Chetchotisakd P; van Wyk J; Teppler H; Kumarasamy N; Molina JM; Emery S; Cooper DA; Boyd MA
    AIDS Res Hum Retroviruses; 2016 Sep; 32(9):841-50. PubMed ID: 27346600
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular diversity of HIV-1 and surveillance of transmitted drug resistance variants among treatment Naïve patients, 5 years after active introduction of HAART in Kuala Lumpur, Malaysia.
    Ong LY; Razak SN; Lee YM; Sri La Sri Ponnampalavanar S; Syed Omar SF; Azwa RI; Tee KK; Kamarulzaman A
    J Med Virol; 2014 Jan; 86(1):38-44. PubMed ID: 24127302
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of genotypic drug resistance mutations on clinical and immunological outcomes in HIV-infected adults on HAART in West Africa.
    Seyler C; Adjé-Touré C; Messou E; Dakoury-Dogbo N; Rouet F; Gabillard D; Nolan M; Toure S; Anglaret X
    AIDS; 2007 May; 21(9):1157-64. PubMed ID: 17502726
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.